Capsaicinoids Enhance Metabolic Rate – An Open Label Study

ISRCTN ISRCTN13980309
DOI https://doi.org/10.1186/ISRCTN13980309
Secondary identifying numbers STUDY00004264
Submission date
08/12/2016
Registration date
15/12/2016
Last edited
31/07/2018
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Nutritional, Metabolic, Endocrine
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
Obesity is a growing problem worldwide. The main reason that people become obese is thought to be due to over-eating and/or not exercising enough. It has also been found that some people with obesity have a lower metabolism than healthy people. Capsaicinoids are a type of chemical which are found in members of the capsicum family of plants (chilies). There is evidence to suggest that capsaicinoids may play a role in metabolism (the breakdown of food and drink into energy). The aim of this study is to look at the effect of capsaicinoids on metabolism for weight management.

Who can participate?
Healthy adults who have a sedentary or lightly active lifestyle.

What does the study involve?
Participants are randomly allocated to one of two group who receive two treatments in a random order, with one week of no treatment in between. The first treatment involved receiving 100mg Capsimax (Capsaicinoids 2 mg) with a meal. The second treatment involves receiving a placebo (dummy drug) with a meal. Before and then 1, 2 and 3 hours after consuming the meal, participants have their metabolic rate calculated using specialized equipment and their heart rate measured. In addition, participants are asked to rate their appetite and interest in eating after 3 hours.

What are the possible benefits and risks of participating?
Participants benefit from learning about their own energy expenditure (metabolism). There are no known risks involved with participating.

Where is the study run from?
Arizona State University (USA)

When is the study starting and how long is it expected to run for?
January 2016 to March 2017

Who is funding the study?
OmniActive Health Technologies Ltd. (India)

Who is the main contact?
Dr Vijaya Juturu
v.juturu@omniactives.com

Contact information

Dr Vijaya Juturu
Scientific

OmniActive Health Technologies
67 East Park Place
Suite 500
Morristown
07960
United States of America

ORCiD logoORCID ID 0000-0002-7397-715X
Phone +91 90 84776953
Email v.juturu@omniactives.com

Study information

Study designSingle blind acute placebo-controlled crossover open label study
Primary study designInterventional
Secondary study designRandomised cross over trial
Study setting(s)School
Study typePrevention
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleCapsaicinoids Enhance Metabolic Rate Using a Novel Metabolic Tracker Breezing Device – An Open Label Study
Study objectivesThe digestion of the meal induce energy expenditure processes that produces heat, increases heart rate due to higher blood circulation, and increases oxygen consumption and carbon dioxide production. The latter is measured via breath analysis and a measurement named metabolic rate or energy expenditure.
Ethics approval(s)Arizona State University- Enterprise and Development IRB, 28/04/2016
Health condition(s) or problem(s) studiedMetabolism
InterventionParticipants are randomised to one of two groups who receive two treatments in a random order.

Group 1: Participants receive 100 mg Capsimax (Capsaicinoids 2 mg) once a day with a meal single administration..
Group 2: Participants receive a placebo (corn starch) once a day with a meal single administration.

After each treatment period, participants undergo one week wash-out before starting the other treatment.

The Breezing® device evaluates people’s energy expenditure (EE) by detecting the rate of oxygen consumption and carbon dioxide generation in breath. It is based on a flow meter for flow detection and a chemical sensing cartridge, which used a cell-phone camera for optical detection. The device is 6.0 oz. (170 g), and 1.8 in × 2.1 in × 4.8 in (4.7 cm × 5.4 cm × 12.3 cm), and connects wirelessly to an iOS/Android mobile device, via Bluetooth®. A QR code with pre-calibrated sensor information is applied on the single-use sensor cartridge, which can be scanned and recognized by the mobile application.
During each measurement, participants breathed through a disposable mouthpiece connected to the Breezing® device for about 1-2 minutes until a total of 6L exhaled breath were measured by the flow meter. The data received on the mobile device is processed and displayed on the application. According to Weir equation, RQ, VO2 and VCO2, the energy expenditure is determined. The participants will be provided with meal including a non-caloric, decaf drink and certain amount of Thomas Plain Bagel and 1/3 less fat Philadelphia cream cheese based on their REE level. The ratio of calorie intake to their REE value was 0.35 for 14 participants and 0.25 for 25 participants. In the meantime, the participants will be served with either a Capsaicinoids pill or a placebo pill. After finishing the meal/pill, the participants’ metabolic rate will be measured at 1, 2, and 3 hours .
Intervention typeSupplement
Primary outcome measureResting Energy Expenditure (Metabolic rate) is measured using breezing equipment (indirect calorimetry) at baseline, 1 hour, 2 hours and 3 hours and data calculated for 24 hours (overall average ∆REE%).

∆REE: REEi – REE0
∆REE (%) : [(REEi – REE0)/REE0] *100%
Secondary outcome measures1. Heart rate measured using i-phone apps and blood pressure are measured using with sphygmomanometer at baseline and after 3 hours
2. Appetite and interest on food intake is measured using a visual analogue scale (0-100 scale) at baseline and at 3 hours
Overall study start date01/05/2016
Completion date15/12/2016

Eligibility

Participant type(s)Healthy volunteer
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants40 subjects Crossover trial
Key inclusion criteria1. English-speaking
2. Adult participants (18 – 80 years old)
3. Sedentary or lightly active lifestyle
4. Able to consent and perform the necessary tests for the study
Key exclusion criteria1. Food allergy or sensitive to gluten
2. Under treatment for chronic conditions/disease such as cancer, burns or obstructive pulmonary diseases
Date of first enrolment10/05/2016
Date of final enrolment30/06/2016

Locations

Countries of recruitment

  • United States of America

Study participating centre

Arizona State University
Center of Bioelectronics and Biosensors
Biodesign Institute
Tempe AZ
85281
United States of America

Sponsor information

OmniActive Health Technologies Ltd.
Industry

Phoenix House, T- 8, A Wing
462 Senapati Bapat Marg, Lower Parel
Mumbai
400 013
India

Website http://omniactives.com/
ROR logo "ROR" https://ror.org/03fxrgb29

Funders

Funder type

Industry

OmniActive Health Technologies
Private sector organisation / For-profit companies (industry)
Location
United States of America

Results and Publications

Intention to publish date31/12/2017
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planPlanned publication in a high-impact peer reviewed journal.
IPD sharing planThe datasets generated during and/or analysed during the current study are/will be available upon request from Dr Erica Forzani (eforzani@asu.edu) or Dr Vijaya Jutruu (v.juturu@omniactives.com).

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 12/06/2017 Yes No

Editorial Notes

31/07/2018: Publication reference added.
22/09/2017: Internal review.